{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2012-D-0307\" sorted by posted_date descending", "rows": [["FDA-2012-D-0307-0071", "FDA", "FDA-2012-D-0307", "Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components", "Other", "Guidance", "2022-05-24T04:00:00Z", 2022, 5, "2022-05-24T04:00:00Z", null, "2024-11-07T00:39:23Z", null, 1, 0, "09000064850df573"], ["FDA-2012-D-0307-0070", "FDA", "FDA-2012-D-0307", "Recommendations To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-05-24T04:00:00Z", 2022, 5, "2022-05-24T04:00:00Z", "2022-05-25T03:59:59Z", "2022-05-25T01:01:14Z", "2022-11119", 0, 0, "09000064850dbd5c"], ["FDA-2012-D-0307-0064", "FDA", "FDA-2012-D-0307", "Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components", "Other", "Guidance", "2020-06-17T04:00:00Z", 2020, 6, "2020-06-17T04:00:00Z", null, "2024-11-06T23:37:22Z", null, 1, 0, "09000064846f63b5"], ["FDA-2012-D-0307-0063", "FDA", "FDA-2012-D-0307", "Recommendations To Reduce the Possible Risk of Transmission of\nCreutzfeldt-Jakob Disease and Variant Creutzfeldt Jakob Disease by Blood and Blood Components; Guidance for Industry; Availability;", "Notice", "Notice of Availability", "2020-06-17T04:00:00Z", 2020, 6, "2020-06-17T04:00:00Z", null, "2020-06-17T12:33:02Z", "2020-13055", 0, 0, "09000064846f5d22"], ["FDA-2012-D-0307-0055", "FDA", "FDA-2012-D-0307", "Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components Guidance for Industry", "Other", "Guidance", "2020-04-03T04:00:00Z", 2020, 4, "2020-04-03T04:00:00Z", null, "2024-11-06T23:34:05Z", null, 1, 0, "090000648448596f"], ["FDA-2012-D-0307-0056", "FDA", "FDA-2012-D-0307", "29 Reference 29 Holmquest et al. No evidence of transfusion transmitted sporadic CJD", "Supporting & Related Material", "Background Material", "2020-04-03T04:00:00Z", 2020, 4, null, null, "2020-04-03T14:35:47Z", null, 0, 0, "09000064844859c1"], ["FDA-2012-D-0307-0037", "FDA", "FDA-2012-D-0307", "Reference 26- Development of Dose-Response Models of Creutzfeldt-Jakob Disease Infection in Nonhuman Primates re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2020-02-25T05:00:00Z", 2020, 2, null, null, "2020-02-25T16:03:56Z", null, 0, 0, "09000064843ae6d8"], ["FDA-2012-D-0307-0038", "FDA", "FDA-2012-D-0307", "Reference 33- The New England Journal of Medicine re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2020-02-25T05:00:00Z", 2020, 2, null, null, "2020-02-25T16:04:02Z", null, 0, 0, "09000064843ae6d7"], ["FDA-2012-D-0307-0031", "FDA", "FDA-2012-D-0307", "Recommendations To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt Jakob Disease by Blood and Blood Components;  Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2020-01-31T05:00:00Z", 2020, 1, "2020-01-31T05:00:00Z", "2020-04-01T03:59:59Z", "2020-02-25T13:29:12Z", "2020-01815", 0, 0, "0900006484315e30"], ["FDA-2012-D-0307-0032", "FDA", "FDA-2012-D-0307", "Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Draft Guidance for Industry", "Other", "Guidance", "2020-01-30T05:00:00Z", 2020, 1, "2020-01-30T05:00:00Z", null, "2024-11-12T23:16:48Z", null, 1, 0, "0900006484317192"], ["FDA-2012-D-0307-0023", "FDA", "FDA-2012-D-0307", "Reference 37-Regulation (EC) No 999_2001 of EU Parliament re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:38:29Z", null, 0, 0, "0900006482d5883c"], ["FDA-2012-D-0307-0013", "FDA", "FDA-2012-D-0307", "Reference 01 - Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by blood and blood products re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T16:24:28Z", null, 0, 0, "0900006482d5882c"], ["FDA-2012-D-0307-0010", "FDA", "FDA-2012-D-0307", "Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2017-12-22T05:00:00Z", 2017, 12, "2017-12-22T05:00:00Z", "2018-03-23T03:59:59Z", "2018-01-06T02:01:16Z", "2017-27569", 0, 0, "0900006482d56ac6"], ["FDA-2012-D-0307-0016", "FDA", "FDA-2012-D-0307", "Referecne 28-Gregori_et_al-2011-Transfusion re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:36:55Z", null, 0, 0, "0900006482d58830"], ["FDA-2012-D-0307-0021", "FDA", "FDA-2012-D-0307", "Reference 35-Schlicter S.J. (1997)TRAP Study re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:58Z", null, 0, 0, "0900006482d58838"], ["FDA-2012-D-0307-0015", "FDA", "FDA-2012-D-0307", "Reference 25-Yang_et_al-2017-Transfusion re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:36:39Z", null, 0, 0, "0900006482d5882e"], ["FDA-2012-D-0307-0020", "FDA", "FDA-2012-D-0307", "Reference 34-King_LR reduced RBC rxn_Tx_'04 re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:48Z", null, 0, 0, "0900006482d58835"], ["FDA-2012-D-0307-0011", "FDA", "FDA-2012-D-0307", "Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Other", "Guidance", "2017-12-22T05:00:00Z", 2017, 12, "2017-12-22T05:00:00Z", "2018-03-23T03:59:59Z", "2024-11-07T01:15:24Z", null, 1, 0, "0900006482d58385"], ["FDA-2012-D-0307-0019", "FDA", "FDA-2012-D-0307", "Reference 32-Transfusion-medicine-epidemiology-review-tmer re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:39Z", null, 0, 0, "0900006482d58833"], ["FDA-2012-D-0307-0018", "FDA", "FDA-2012-D-0307", "Reference 31-McCutcheon_et_al-2011-PloSOne re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:23Z", null, 0, 0, "0900006482d58832"], ["FDA-2012-D-0307-0022", "FDA", "FDA-2012-D-0307", "Referenec 36-Bowden_LR v seroneg_Blood '95 re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:38:22Z", null, 0, 0, "0900006482d5883b"], ["FDA-2012-D-0307-0024", "FDA", "FDA-2012-D-0307", "Reference 38-FDA Transmissible Spongiform Encephalopathies Advisory Committee re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:38:38Z", null, 0, 0, "0900006482d5883d"], ["FDA-2012-D-0307-0014", "FDA", "FDA-2012-D-0307", "Reference 19-Swiss Med Wkly re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T16:24:59Z", null, 0, 0, "0900006482d5882d"], ["FDA-2012-D-0307-0017", "FDA", "FDA-2012-D-0307", "Reference 29-Harvey_et_al-2015-Transfusion re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2020-02-25T15:37:08Z", null, 0, 0, "0900006482d58831"], ["FDA-2012-D-0307-0012", "FDA", "FDA-2012-D-0307", "Reference List re Amendment to \u2018\u2018Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;\u2019\u2019 Draft Guidance for Industry; Availability", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T16:24:07Z", null, 0, 0, "0900006482d587fd"], ["FDA-2012-D-0307-0009", "FDA", "FDA-2012-D-0307", "References List - Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products", "Supporting & Related Material", "Background Material", "2016-01-15T05:00:00Z", 2016, 1, null, null, "2016-01-15T16:03:51Z", null, 0, 0, "0900006481e0d8a6"], ["FDA-2012-D-0307-0008", "FDA", "FDA-2012-D-0307", "Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry", "Other", "Guidance", "2016-01-14T05:00:00Z", 2016, 1, "2016-01-14T05:00:00Z", null, "2024-11-11T21:21:28Z", null, 1, 0, "0900006481e0dc4c"], ["FDA-2012-D-0307-0007", "FDA", "FDA-2012-D-0307", "Revised Preventive Measures To Reduce the Possible Risk of\nTransmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob\nDisease by Blood and Blood Products; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2016-01-14T05:00:00Z", 2016, 1, "2016-01-14T05:00:00Z", null, "2016-01-14T15:19:15Z", "2016-00536", 0, 0, "0900006481e0d2aa"], ["FDA-2012-D-0307-0002", "FDA", "FDA-2012-D-0307", "Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc.", "Other", "Guidance", "2012-06-12T04:00:00Z", 2012, 6, "2012-06-12T04:00:00Z", null, "2012-06-12T16:37:12Z", null, 0, 0, "09000064810413e8"], ["FDA-2012-D-0307-0001", "FDA", "FDA-2012-D-0307", "Draft Guidance for Industry: Revised Preventive Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease, etc.; Amendment", "Notice", "Notice of Availability", "2012-06-11T04:00:00Z", 2012, 6, "2012-06-11T04:00:00Z", "2012-09-11T03:59:59Z", "2012-09-20T02:01:13Z", "2012-14034", 0, 0, "0900006481040b4c"]], "truncated": false, "filtered_table_rows_count": 30, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2012-D-0307"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2012-D-0307", "results": [{"value": "FDA", "label": "FDA", "count": 30, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2012-D-0307", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 17, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 7, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&document_type=Other", "selected": false}, {"value": "Notice", "label": "Notice", "count": 6, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&document_type=Notice", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2012-D-0307", "results": [{"value": 2017, "label": 2017, "count": 15, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2017", "selected": false}, {"value": 2020, "label": 2020, "count": 8, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2020", "selected": false}, {"value": 2016, "label": 2016, "count": 3, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2016", "selected": false}, {"value": 2012, "label": 2012, "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2012", "selected": false}, {"value": 2022, "label": 2022, "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&posted_year=2022", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "title", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet=title"}, {"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet=comment_start_date"}, {"name": "comment_end_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet=comment_end_date"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2012-D-0307&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 9.380975039675832, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}